一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Dato-DXd；Durvalumab；Paclitaxel；Nab-paclitaxel；Gemcitabine；Carboplatin；Pembrolizumab，当前状态为招募中。登记地点显示中国安阳、北京、蚌埠、长春等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Dato-DXd；Durvalumab；Paclitaxel；Nab-paclitaxel；Gemcitabine；Carboplatin；Pembrolizumab · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 安阳
- Research Site · 北京
- Research Site · 蚌埠
- Research Site · 长春
- Research Site · 长沙
- Research Site · 成都
- Research Site · 重庆
- Research Site · 福州
- Research Site · 广州
- Research Site · 杭州
- Research Site · 哈尔滨
- Research Site · 合肥
- Research Site · 济南
- Research Site · 梅州
- Research Site · 南昌
- Research Site · 南京
- Research Site · 南宁
- Research Site · 山东省
- Research Site · 上海
- Research Site · 沈阳
- Research Site · 太原
- Research Site · 天津
- Research Site · 温州
- Research Site · 武汉
- Research Site · 西安
- Research Site · 厦门
- Research Site · Xintai
- Research Site · 徐州
- Research Site · 湛江
- Research Site · 郑州
公开的入选条件
- * Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.
- * ECOG PS 0 or 1.
- * Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant sign
- * PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.
- * No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
- \- Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.
- * Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).
- * Measurable disease as per RECIST 1.1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06103864；登记信息更新于 2026-09-25。